Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Interest Expenses (2022 - 2025)

Autolus Therapeutics' Interest Expenses history spans 4 years, with the latest figure at $22.8 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 174.06% year-over-year to $22.8 million; the TTM value through Dec 2025 reached $36.7 million, up 294.56%, while the annual FY2025 figure was $36.7 million, 294.56% up from the prior year.
  • Interest Expenses reached $22.8 million in Q4 2025 per AUTL's latest filing, up from $10.5 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $30.1 million in Q4 2023 to a low of -$30.8 million in Q4 2024.
  • Average Interest Expenses over 4 years is $6.2 million, with a median of $5.0 million recorded in 2023.
  • Peak YoY movement for Interest Expenses: surged 771.51% in 2023, then plummeted 202.35% in 2024.
  • A 4-year view of Interest Expenses shows it stood at $3.5 million in 2022, then soared by 771.51% to $30.1 million in 2023, then tumbled by 202.35% to -$30.8 million in 2024, then soared by 174.06% to $22.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Interest Expenses are $22.8 million (Q4 2025), $10.5 million (Q3 2025), and -$6.8 million (Q2 2025).